Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intermittent Fasting Following Acute Ischemic Stroke

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03789409
Recruitment Status : Recruiting
First Posted : December 28, 2018
Last Update Posted : July 10, 2019
Sponsor:
Information provided by (Responsible Party):
Chang Ho Hwang, Ulsan University Hospital

Brief Summary:
Despite numerous kinds of evidence on functional health and CNS protection of intermittent fasting after injuries were found in many brain-, and spinal cord-damaged animal models, there has yet to be any clinical study of intermittent fasting after acute ischemic cerebral infarction. The aim of this study is to evaluate the neurological, functional and clinical efficacy of intermittent fasting in patients after acute ischemic stroke.

Condition or disease Intervention/treatment Phase
Ischemic Stroke Intermittent Fasting Dietary Supplement: Intermittent Fasting Not Applicable

Detailed Description:
In order to verify the validity and clinical efficacy of intermittent fasting for neurological and functional effects of ischemic cerebral infarction, the first ischemic stroke (diagnosed within 1 year through brain MRI / CT) patients will be randomly assigned to intermittent fasting group or control group. In both groups, physical therapy, occupational therapy and speech therapy will be provided during 3 hours in total a day. The intermittent fasting group should maintain intermittent fasting for no less than 12 hours or more every day during the rehabilitation period (at least 1 week), and the control group is able to eat all of the hospital meals and all the participants want without any time limit. The efficacy of intermittent fasting is to be verified by performing the electro-physiological tests and functional evaluations before participation, 1st week, 2nd weeks after participation, before discharge, 3 months, and 6 months after the stroke onset.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 68 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Intermittent Fasting Following Acute Ischemic Stroke: Prospective, Randomized, Parallel Group, Controlled Trial
Actual Study Start Date : March 4, 2019
Estimated Primary Completion Date : January 31, 2020
Estimated Study Completion Date : January 31, 2020

Arm Intervention/treatment
Experimental: Intermittent Fasting
Over rehabilitation treatment during and admission (at least 1 week), intermittent fasting (IF) for more than 12 hours (water can be allowed). For subgroup assignment, participants can choose IF1 (eat early in the evening and late in the morning) or Post-IF2 (eat the remaining two meals without breakfast), depending on own their faver.
Dietary Supplement: Intermittent Fasting
The aforementioned intermittent fasting in arm/group descriptions.

No Intervention: Ad libitium
Participants will be allowed to have hospital meals and all the desired intake without time limit.



Primary Outcome Measures :
  1. Change of Surface electromyography [ Time Frame: 1 day before the initiation of intervention, and 6 months after the stroke onset ]
    root mean square and root peak square of compound motor action potential


Secondary Outcome Measures :
  1. Change of Korean-modified Barthel index [ Time Frame: 1 day before the initiation of intervention and 3rd week after start of intervention, 3 months and 6 months after the stroke onset ]
    Korean version-Modified Barthel Index (minimum of 0 and maximum scores of 100); higher values and a better outcome.


Other Outcome Measures:
  1. Change of Mini mental status exam [ Time Frame: 1 day before the initiation of intervention and 3rd week after start of intervention, 3 months and 6 months after the stroke onset ]
    Mini mental status exam(minimum of 0 and maximum scores of 30); higher values and a better outcome.

  2. Change of Beck depression inventory [ Time Frame: 1 day before the initiation of intervention and 3rd week after start of intervention, 3 months and 6 months after the stroke onset ]
    Beck depression inventory(minimum of 0 and maximum scores of 63); higher values and a worse outcome.

  3. Change of Wecsler aphasia battery [ Time Frame: 1 day before the initiation of intervention and 3rd week after start of intervention, 3 months and 6 months after the stroke onset ]
    Wecsler aphasia battery(minimum of 0 and maximum scores of 100); higher values and a better outcome.

  4. Change of Berg balance scale [ Time Frame: 1 day before the initiation of intervention and 3rd week after start of intervention, 3 months and 6 months after the stroke onset ]
    Berg balance scale(minimum of 0 and maximum scores of 56); higher values and a better outcome.

  5. Change of Functional Ambulation Category [ Time Frame: 1 day before the initiation of intervention and 3rd week after start of intervention, 3 months and 6 months after the stroke onset ]
    Functional Ambulation Category(minimum of 0 and maximum scores of 5); higher values and a better outcome.

  6. Change of Motricity Index [ Time Frame: 1 day before the initiation of intervention and 3rd week after start of intervention, 3 months and 6 months after the stroke onset ]
    Motricity Index(minimum of 0 and maximum scores of 99); higher values and a better outcome.

  7. Change of 10m walking test [ Time Frame: 1 day before the initiation of intervention and 3rd week after start of intervention, 3 months and 6 months after the stroke onset ]
    10m walking test

  8. Change of Grasping force (kg) [ Time Frame: 1 day before the initiation of intervention and 3rd week after start of intervention, 3 months and 6 months after the stroke onset ]
    Grasping force (kg)

  9. Change of 9-hole pegboard [ Time Frame: 1 day before the initiation of intervention and 3rd week after start of intervention, 3 months and 6 months after the stroke onset ]
    9-hole pegboard

  10. Change of Jebsen Taylor test [ Time Frame: 1 day before the initiation of intervention and 3rd week after start of intervention, 3 months and 6 months after the stroke onset ]
    Jebsen-Taylor Hand Function Test

  11. Change of Nottingham sensory scale [ Time Frame: 1 day before the initiation of intervention and 3rd week after start of intervention, 3 months and 6 months after the stroke onset ]
    Nottingham sensory scale(minimum of 0 and maximum scores of 20); higher values and a better outcome.

  12. Change of Arm motor Fugl-Mayer scale [ Time Frame: 1 day before the initiation of intervention and 3rd week after start of intervention, 3 months and 6 months after the stroke onset ]
    Arm motor Fugl-Mayer scale; wrist & hand/proximal arm(minimum of 0 and maximum scores of 24 and of 34, respectively ); higher values and a better outcome.

  13. Change of Stroke impact scale [ Time Frame: 1 day before the initiation of intervention and 3rd week after start of intervention, 3 months and 6 months after the stroke onset ]
    Hand motor, Stroke Impact Scale (minimum of 12 and maximum scores of 60); higher values and a better outcome.

  14. Change of Ashworth scale [ Time Frame: 1 day before the initiation of intervention and 3rd week after start of intervention, 3 months and 6 months after the stroke onset ]
    Ashworth scale; elbow, wrist, knee & ankle(minimum of 0 and maximum scores of 4); higher values and a worse outcome.

  15. Change of Knee joint kinesthesia [ Time Frame: 1 day before the initiation of intervention and 3rd week after start of intervention, 3 months and 6 months after the stroke onset ]
    The smallest iso-kinetic angle from which the participants could detect any passive flexion or extension movement of their own knee, using Biodex; (minimum of 0 and maximum scores of 360 degree); higher values and a worse outcome.

  16. Change of Behavioral inatention test [ Time Frame: 1 day before the initiation of intervention and 3rd week after start of intervention, 3 months and 6 months after the stroke onset ]
    Behavioral inatention test(minimum of 0 and maximum scores of 146); higher values and a better outcome.

  17. Change of Apraxia screen of Tulia [ Time Frame: 1 day before the initiation of intervention and 3rd week after start of intervention, 3 months and 6 months after the stroke onset ]
    Apraxia screen of (minimum of 0 and maximum scores of 12); higher values and a better outcome.

  18. Change of motor evoked potential [ Time Frame: 1 day before the initiation of intervention, and 6 months after the stroke onset ]
    Amplitude (uV) of motor evoked potential was recorded on abductor pollicis brevis and extentor digitorum brevis following trans-cranial magnetic stimulation for cortico-spinal excitability.

  19. Change of Weight [ Time Frame: 1 day before the start of intervention and 1 weeks and 2 weeks after the start of intervention ]
    Weight (Kg)

  20. Change of Temperature [ Time Frame: 1 day before the start of intervention and 1 weeks and 2 weeks after the start of intervention ]
    temperature (Celsius)

  21. Change of Serum glucose level [ Time Frame: 1 day before the start of intervention and 1 weeks and 2 weeks after the start of intervention ]
    Serum glucose level (mg/ml)

  22. Change of Hypoglycemia-related severity [ Time Frame: every day following the start of intervention until 2 weeks of intervention ]
    Assessment of hypoglycemic symptoms using Likert scale (minimum of 0 and maximum scores of 10); higher values and a worse outcome.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients who was diagnosed first ischemic stroke within preceeding 1 year through brain MRI/CT

Exclusion Criteria:

  • Musculo-skeletal disease with limbs malformation or joint contracture
  • Weigh more than 135 kg or taller than 195 cm
  • Diabetes mellitus
  • unstable patient in neurology
  • Refusal of participation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03789409


Contacts
Layout table for location contacts
Contact: Chang Ho Hwang +82-52-250-7210 chhwang1220ciba@gmail.com

Locations
Layout table for location information
Korea, Republic of
Ulsan University Hospital Recruiting
Ulsan, Korea, Republic of, 682-714
Contact: Chang Ho Hwang, M.D., Ph.D.    +82-52-250-7210    chhwang1220ciba@gmail.com   
Principal Investigator: Chang Ho Hwang, M.D., Ph.D.         
Sponsors and Collaborators
Ulsan University Hospital
Investigators
Layout table for investigator information
Study Director: Chang Ho Hwang, M.D., Ph.D. Ulsan University Hospital

Layout table for additonal information
Responsible Party: Chang Ho Hwang, Associate Professor, Ulsan University Hospital
ClinicalTrials.gov Identifier: NCT03789409     History of Changes
Other Study ID Numbers: chhwang11
First Posted: December 28, 2018    Key Record Dates
Last Update Posted: July 10, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Stroke
Cerebral Infarction
Ischemia
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes
Brain Infarction
Brain Ischemia